MARTHA ALVARADO-IBARRA

Dr. MARTHA ALVARADO-IBARRA

HOSPITAL ANGELES INTERLOMAS, Huixquilucan, México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2009 in British Journal of Cancer
Verified
Journal Article
Open access
JFJ Flores-Lujano
J Flores-Lujano
MPMaría Luisa Perez-Saldivar
María Luisa Perez-Saldivar
EFEzequiel M. Fuentes-Pananá
Ezequiel M. Fuentes-Pananá
CGC Gorodezky
C Gorodezky
RBR Bernaldez-Rios
R Bernaldez-Rios
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Background: Methods: Results: Conclusion:

7 May 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
ECErick Crespo‐Solis
Erick Crespo‐Solis
KEKarla Espinosa‐Bautista
Karla Espinosa‐Bautista
MARTHA ALVARADO-IBARRAMARTHA ALVARADO-IBARRA
MARTHA ALVARADO-IBARRA
EREtta Rozen‐Fuller
Etta Rozen‐Fuller
FPFernando Pérez‐Rocha
Fernando Pérez‐Rocha
RDRoberta Demichelis‐Gómez
Roberta Demichelis‐Gómez
Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the clonal expansion of hematopoietic lymphoid progenitors. With new target therapies, the survival of adults with ALL has improved in the past few decades. Unfortunately, there are no large ALL patient series in many Latin American countries. Data from the Acute Leukemia Workgroup that includes five Mexico City referral centers were used. Survival was estimated for adult patients with ALL during 2009–2015. In total, 559 adults with ALL were included. The median age was 28 years; 67% were classified into the adolescent and young adult group. Cytogenetic information was available in 54.5% of cases. Of the 305 analyzed cases, most had a normal caryotype (70.5%) and Philadelphia‐positive was present in 16.7%. The most commonly used treatment regimen was hyper‐CVAD. In approximately 20% of cases, there was considerable delay in the administration of chemotherapy. Primarily refractory cases accounted for 13.1% of patients. At the time of analysis, 26.7% of cases had survived. The 3‐year overall survival was 22.1%. The main cause of death was disease progression in 228 (55.6%). Clinical and public health strategies are needed to improve diagnosis, treatment and survivorship care for adult with ALL. This multicentric report represents the largest series in Mexico of adult ALL patients in which a survival analysis and risk identification were obtained.

14 September 2022 in Frontiers in Public Health
Verified
Journal Article
Open access
JFJanet Flores-Lujano
Janet Flores-Lujano
DDDavid Aldebarán Duarte-Rodríguez
David Aldebarán Duarte-Rodríguez
EJElva Jiménez-Hernández
Elva Jiménez-Hernández
JMJorge Alfonso Martín-Trejo
Jorge Alfonso Martín-Trejo
AAAldo Allende-López
Aldo Allende-López
JUAN MANUEL MEJIA-ARANGUREJUAN MANUEL MEJIA-ARANGURE
JUAN MANUEL MEJIA-ARANGURE
Introduction: Over the years, the Hispanic population living in the United States has consistently shown high incidence rates of childhood acute leukemias (AL). Similarly, high AL incidence was previously observed in Mexico City (MC). Here, we estimated the AL incidence rates among children under 15 years of age in MC during the period 2010–2017.Methods: The Mexican Interinstitutional Group for the Identification of the Causes of Childhood Leukemia conducted a study gathering clinical and epidemiological information regarding children newly diagnosed with AL at public health institutions of MC. Crude age incidence rates (cAIR) were obtained. Age-standardized incidence rates worldwide (ASIRw) and by municipalities (ASIRm) were calculated by the direct and indirect methods, respectively. These were reported per million population <15 years of age; stratified by age group, sex, AL subtypes, immunophenotype and gene rearrangements.Results: A total of 903 AL cases were registered. The ASIRw was 63.3 (cases per million) for AL, 53.1 for acute lymphoblastic leukemia (ALL), and 9.4 for acute myeloblastic leukemia. The highest cAIR for AL was observed in the age group between 1 and 4 years (male: 102.34 and female: 82.73). By immunophenotype, the ASIRw was 47.3 for B-cell and 3.7 for T-cell. The incidence did not show any significant trends during the study period. The ASIRm for ALL were 68.6, 66.6 and 62.8 at Iztacalco, Venustiano Carranza and Benito Juárez, respectively, whereas, other municipalities exhibited null values mainly for AML.Conclusion: The ASIRw for childhood AL in MC is among the highest reported worldwide. We observed spatial heterogeneity of rates by municipalities. The elevated AL incidence observed in Mexican children may be explained by a combination of genetic background and exposure to environmental risk factors.

22 October 2013 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
MDMarcela Deffis-Court
Marcela Deffis-Court
MARTHA ALVARADO-IBARRAMARTHA ALVARADO-IBARRA
MARTHA ALVARADO-IBARRA
GRGuillermo J. Ruiz-Argüelles
Guillermo J. Ruiz-Argüelles
ARAdriana Rosas-López
Adriana Rosas-López
GBGeorgina Barrera-Lumbreras
Georgina Barrera-Lumbreras
ECErick Crespo-Solís
Erick Crespo-Solís

1 January 2021 in World Journal of Oncology
Verified
Journal Article
Open access
PDF file
EHEleazar Hernandez-Ruiz
Eleazar Hernandez-Ruiz
MARTHA ALVARADO-IBARRAMARTHA ALVARADO-IBARRA
MARTHA ALVARADO-IBARRA
LLLourdes Esthela Juan Lien-Chang
Lourdes Esthela Juan Lien-Chang
LBLuisa Banda-Garcia
Luisa Banda-Garcia
JAJorge Luis Aquino-Salgado
Jorge Luis Aquino-Salgado
JPJuan Manuel Perez-Zuniga
Juan Manuel Perez-Zuniga
Epidemiology and Clinical Characteristics of Non-Hodgkin Lymphoma in Mexico

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
RDRoberta Demichelis-Gómez
Roberta Demichelis-Gómez
MARTHA ALVARADO-IBARRAMARTHA ALVARADO-IBARRA
MARTHA ALVARADO-IBARRA
JVJule Vasquez-Chávez
Jule Vasquez-Chávez
NDNancy Delgado-López
Nancy Delgado-López
CGCynthia Gómez-Cortés
Cynthia Gómez-Cortés
DGDavid Gómez-Almaguer
David Gómez-Almaguer
The COVID-19 pandemic is a colossal challenge for global health; nonetheless, specific subgroups face considerably higher risks for infection and mortality. Among patients with malignant diseases, those with hematologic neoplasms are at a higher risk for poor outcomes. The objective of this study was to register treatment modifications associated with the COVID-19 pandemic and their short-term consequences in Latin America. Multicenter, prospective, observational, cohort study including patients older than 14 years from 14 centers in four countries (Mexico, Peru, Guatemala, and Panama) who had a confirmed diagnosis of acute leukemia, and who were undergoing active treatment since the first COVID-19 case in each country until the cutoff on July 15, 2020. We recruited 635 patients. Treatment modifications because of the COVID-19 pandemic were reported in 40.8% of cases. The main reason for such modifications was logistic issues (55.0%) and the most frequent modification was chemotherapy delay (42.0%). A total of 13.1% patients developed COVID-19 disease, with a mortality of 37.7%. Several factors were identified as independently associated with mortality, including a diagnosis of acute myeloid leukemia (odds ratio 2.38 [95% CI, 1.47 to 3.84]; P < .001), while the use of telemedicine was identified as a protective factor (odds ratio 0.36 [95% CI, 0.18 to 0.82]; P = .014). These results highlight the collateral damage of COVID-19 in oncology patients.